GREENWICH LIFESCIENCES, INC. Warrants and Rights Outstanding
GREENWICH LIFESCIENCES, INC. (GLSI) had Warrants and Rights Outstanding of $37.98 thousand as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:WarrantsAndRightsOutstanding · last filed 2025-08-14
- 2025-06-30: Warrants and Rights Outstanding $37.98K.
- 2025-03-31: Warrants and Rights Outstanding $47.46K.
- 2024-12-31: Warrants and Rights Outstanding $81.55K.
- 2024-09-30: Warrants and Rights Outstanding $144.90K.
| Period end | Warrants and Rights Outstanding |
|---|---|
| 2025-06-30 | $37.98K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $47.46K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $81.55K 10-K · filed 2025-04-15 |
| 2024-09-30 | $144.90K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $203.20K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $257.27K 10-Q · filed 2024-05-20 |
| 2023-12-31 | $67.23K 10-K · filed 2024-04-15 |
| 2023-09-30 | $33.34K 10-Q · filed 2023-10-19 |
| 2023-06-30 | $49.68K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $133.20K 10-Q · filed 2023-05-22 |
| 2022-12-31 | $161.64K 10-K · filed 2023-03-31 |
| 2022-09-30 | $38.58K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $25.87K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $250.81K 10-Q · filed 2022-05-20 |
| 2021-12-31 | $345.83K 10-K · filed 2022-03-21 |
| 2020-12-31 | $2.95M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |